Sequenom has appointed Charles Slacik to its board of directors. Slacik has served as chief financial officer and senior vice president of finance for Beckman Coulter since 2006. Previously, he was executive vice president and chief financial officer at Watson Pharmaceuticals, a specialty pharmaceutical company; and senior vice president and chief financial officer at CR Bard, which develops medical technologies in the fields of vascular, urology, oncology, and surgical specialty products.
Slacik holds a BS in accounting and finance from the University of Connecticut and is a certified public accountant.
Foundation Medicine has appointed Kevin Krenitsky to chief operating officer, where he will be responsible for the commercialization of the company's sequencing-based cancer diagnostic test. Krenitsky has 15 years experience in the field, most recently at Enzo Clinical Labs, where he served as president. Previously, he was CEO at BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests; and CEO at Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He has also held senior positions in Genomics Collaborative. He holds a BS in business management from the University of Scranton and an MD from Jefferson Medical College.
Zsofia Stadler has been awarded a three-year $450,000 grant to use sequencing to study the genetics of sporadic cancers from the Damon Runyon Cancer Research Foundation, which gives grants to early-career physician-scientists conducting patient-oriented cancer research.
Stadler is a clinical geneticist at Memorial Sloan-Kettering Cancer Center in New York. She is working to determine the genetic basis of sporadic cancers in young adults and will test the hypothesis that de novo chromosomal changes in the genome are associated with testicular germline cancer by using sequencing technology to compare the whole genomes of patients to their parents.